2147706-60-1
Chemical Structure
Deuruxolitinib phosphate
Synonym(s): CTP-543 phosphate; Ruxolitinib-d8 phosphate; INCB18424-d8 (phospha
- CAS No.: 2147706-60-1
- Formula:C17H13D8N6O4P
- Molecular Weight:412.41
IUPAC Name: (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-(cyclopentyl-2,2,3,3,4,4,5,5-d8)propanenitrile phosphate
InChIKey: JFMWPOCYMYGEDM-NTVOUFPTSA-N
SMILES: O=P(O)(O)O.N#CC[C@H](C1C([2H])([2H])C([2H])([2H])C([2H])([2H])C1([2H])[2H])N2C=C(C=N2)C3=C4C(NC=C4)=NC=N3
Biological Activity: Deuruxolitinib phosphate (CTP-543 phosphate; Ruxolitinib-d8 phosphate) is a deuterated analog of Ruxolitinib (HY-50856) and an orally active, selective inhibitor of JAK1 and JAK2. Deuruxolitinib phosphate blocks Janus kinase-mediated cytokine receptor signaling and proinflammatory cytokine gene expression. Deuruxolitinib phosphate is primarily metabolized in the liver via CYP2C9. Deuruxolitinib phosphate promotes scalp hair regrowth in severe chronic alopecia areata. Deuruxolitinib phosphate is used in alopecia areata-related research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Deuruxolitinib phosphate | Deuruxolitinib phosphate (CTP-543 phosphate; Ruxolitinib-d8 phosphate) is a deuterated analog of Ruxolitinib (HY-50856) and an orally active, selective inhibitor of JAK1 and JAK2. Deuruxolitinib phosphate blocks Janus kinase-mediated cytokine receptor signaling and proinflammatory cytokine gene expression. Deuruxolitinib phosphate is primarily metabolized in the liver via CYP2C9. Deuruxolitinib phosphate promotes scalp hair regrowth in severe chronic alopecia areata. Deuruxolitinib phosphate is used in alopecia areata-related research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Tsianakas A, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial. Journal of the American Academy of Dermatology. 2026 Apr;94(4):1134-1143.
- [2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019q Feb;53(2):211-216. [Content Brief]
